These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28658110)

  • 1. The clinical outcome correlations between radiation dose and pretreatment metabolic tumor volume for radiotherapy in head and neck cancer: A retrospective analysis.
    Yang SN; Chiou YR; Zhang GG; Chou KT; Huang TC
    Medicine (Baltimore); 2017 Jun; 96(26):e7186. PubMed ID: 28658110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
    Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
    Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.
    Kao CH; Lin SC; Hsieh TC; Yen KY; Yang SN; Wang YC; Liang JA; Hua CH; Chen SW
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1297-305. PubMed ID: 22532254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of [
    Pisani C; Vigna L; Mastroleo F; Loi G; Amisano V; Masini L; Deantonio L; Aluffi Valletti P; Sacchetti G; Krengli M
    Radiat Oncol; 2021 Mar; 16(1):57. PubMed ID: 33743759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretreatment (18)F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy.
    Chen SW; Hsieh TC; Yen KY; Liang JA; Kao CH
    Clin Nucl Med; 2014 May; 39(5):e296-300. PubMed ID: 24217547
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
    Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET metabolic tumor parameters for the reirradiation of recurrent head and neck cancer.
    Velez MA; Veruttipong D; Wang PC; Abemayor E; St John M; TenNapel M; Chen AM
    Laryngoscope; 2018 Oct; 128(10):2345-2350. PubMed ID: 29573279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E
    Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance and predictive performance of volume-based parameters of F-18 FDG PET/CT in squamous cell head and neck cancers.
    Sager S; Asa S; Yilmaz M; Uslu L; Vatankulu B; Halaç M; Sönmezoglu K; Kanmaz B
    J Cancer Res Ther; 2014; 10(4):922-6. PubMed ID: 25579529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
    Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Fowler A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):801-811. PubMed ID: 28004135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
    Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment tumor SUV
    Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
    Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma.
    Koyasu S; Nakamoto Y; Kikuchi M; Suzuki K; Hayashida K; Itoh K; Togashi K
    AJR Am J Roentgenol; 2014 Apr; 202(4):851-8. PubMed ID: 24660716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.